Home » ABMAXIS ACHIEVES MILESTONE IN COLLABORATION WITH MERCK
ABMAXIS ACHIEVES MILESTONE IN COLLABORATION WITH MERCK
Abmaxis, Inc., a privately held biopharmaceutical company, today announced that it has achieved a major milestone under its collaboration agreement with Merck & Co., Inc. Under the terms of the agreement, Abmaxis was to optimize an undisclosed Merck human monoclonal antibody for potential therapeutic use. The Abmaxis team has successfully re-engineered Merck's human monoclonal antibody and improved antibody affinity more than 70-fold while retaining its specificity, triggering a milestone payment from Merck.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-18-2005/0004171411&EDATE=)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May